Literature DB >> 18691923

Unclassified polysaccharidosis of the heart and skeletal muscle in siblings.

Benedikt Schoser1, Claudio Bruno, Hans-Christian Schneider, Yoon S Shin, Teodor Podskarbi, Lev Goldfarb, Wolfgang Müller-Felber, Josef Müller-Höcker.   

Abstract

We describe a 15-year-old boy and his 19-year-old sister with progressive dilated cardiomyopathy and mild non-progressive proximal lower limb myopathy, secondary to the accumulation of amylopectin-like fibrillar glycogen, (polyglucosan) bodies, in heart and skeletal muscle. Evidence of idiopathic amylopectinosis or polysaccharidosis was demonstrated in heart and skeletal muscle tissue by histology, electron microscopy, biochemical, and genetic analysis. In both siblings the heart muscle stored PAS-positive, proteinase-k resistant and partly diastase resistant granulo-filamentous material, simulating polyglucosan bodies. Glycogen branching enzyme activity, and phosphofructokinase enzyme activity, measured in skeletal muscle tissue and explanted heart tissue were all within the normal limits, however glycogen content was elevated. Furthermore, GBE1, PRKAG2, desmin, alphabeta-crystallin, ZASP, myotilin, and LAMP-2 gene sequencing revealed no mutation, excluding e.g. glycogen storage disease type 4 and desmin-related myofibrillar cardiomyopathies. In both patients the diagnosis of an idiopathic polysaccharidosis with progressive dilated cardiomyopathy was made, requiring heart transplantation at age 13 and 14, respectively. Both patients belong to an autosomal recessive group of biochemically and genetically unclassified severe vacuolar glycogen storage disease of the heart and skeletal muscle. Up to now unidentified glycogen synthesis or glycogen degradation pathways are supposed to contribute to this idiopathic glycogen storage disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691923      PMCID: PMC2583439          DOI: 10.1016/j.ymgme.2008.07.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  19 in total

1.  Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy.

Authors:  Michael Arad; D Woodrow Benson; Antonio R Perez-Atayde; William J McKenna; Elizabeth A Sparks; Ronald J Kanter; Kate McGarry; J G Seidman; Christine E Seidman
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  Glycogen storage disease type IV, amylopectinosis.

Authors:  B Levin; E A Burgess; P E Mortimer
Journal:  Arch Dis Child       Date:  1968-10       Impact factor: 3.791

3.  Surprises of genetic engineering: a possible model of polyglucosan body disease.

Authors:  N Raben; M Danon; N Lu; E Lee; L Shliselfeld; A V Skurat; P J Roach; J C Lawrence ; O Musumeci; S Shanske; S DiMauro; P Plotz
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

Review 4.  Phosphofructokinase deficiency; past, present and future.

Authors:  Hiromu Nakajima; Nina Raben; Tomoya Hamaguchi; Tomoyuki Yamasaki
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

Review 5.  The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies.

Authors:  Shimon W Moses; Ruti Parvari
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

6.  Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy.

Authors:  Michael Arad; Ivan P Moskowitz; Vickas V Patel; Ferhaan Ahmad; Antonio R Perez-Atayde; Douglas B Sawyer; Mark Walter; Guo H Li; Patrick G Burgon; Colin T Maguire; David Stapleton; Joachim P Schmitt; X X Guo; Anne Pizard; Sabina Kupershmidt; Dan M Roden; Charles I Berul; Christine E Seidman; J G Seidman
Journal:  Circulation       Date:  2003-06-02       Impact factor: 29.690

Review 7.  Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome.

Authors:  M H Gollob
Journal:  Biochem Soc Trans       Date:  2003-02       Impact factor: 5.407

8.  Fatal infantile neuromuscular presentation of glycogen storage disease type IV.

Authors:  Stacey K H Tay; Hasan O Akman; Wendy K Chung; Michael G Pike; Francesco Muntoni; Arthur P Hays; Sara Shanske; Stephanie J Valberg; James R Mickelson; Kurenai Tanji; Salvatore DiMauro
Journal:  Neuromuscul Disord       Date:  2004-04       Impact factor: 4.296

Review 9.  Control of glycogen deposition.

Authors:  Juan C Ferrer; Cristián Favre; Roger R Gomis; Josep M Fernández-Novell; Mar García-Rocha; Núria de la Iglesia; Emili Cid; Joan J Guinovart
Journal:  FEBS Lett       Date:  2003-07-03       Impact factor: 4.124

10.  Clinical and genetic heterogeneity of branching enzyme deficiency (glycogenosis type IV).

Authors:  C Bruno; O P van Diggelen; D Cassandrini; M Gimpelev; B Giuffrè; M A Donati; P Introvini; A Alegria; S Assereto; L Morandi; M Mora; E Tonoli; S Mascelli; M Traverso; E Pasquini; M Bado; L Vilarinho; G van Noort; F Mosca; S DiMauro; F Zara; C Minetti
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

View more
  3 in total

Review 1.  Update on polyglucosan storage diseases.

Authors:  Giovanna Cenacchi; V Papa; R Costa; V Pegoraro; R Marozzo; M Fanin; C Angelini
Journal:  Virchows Arch       Date:  2019-07-30       Impact factor: 4.064

2.  251st ENMC international workshop: Polyglucosan storage myopathies 13-15 December 2019, Hoofddorp, the Netherlands.

Authors:  Pascal Laforêt; Anders Oldfors; Edoardo Malfatti; John Vissing
Journal:  Neuromuscul Disord       Date:  2021-01-23       Impact factor: 4.296

Review 3.  Heart Disease in Disorders of Muscle, Neuromuscular Transmission, and the Nerves.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.